This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): Interleukin 20, NNC0109-0012, NNC109-0012, Anti-IL-20
Description: Interleukin-20 (IL-20) is a protein belonging to the IL-10 family of cytokines. IL-20 is produced by activated keratinocytes and monocytes and transmits an intracellular signal through two distinct cell-surface receptor complexes on keratinocytes and other epithelial cells. IL-20 regulates proliferation and differentiation of keratinocytes during inflammation, particularly inflammation associated with the skin. In addition, IL-20 also causes cell expansion of multipotential hematopoietic progenitor cells.
Deal Structure: In September 2001, Novo Nordisk exercised options to license three proteins fromZymoGenetics in the research phase, including interleukin 20 (IL-20;inflammation).
In March 2004, ZymoGenetics announced the signing of a license agreement with Novo Nordisk for exclusive rights in North America to ZymoGenetics' patents covering IL-20. As part of the licensing agreement, Novo Nordisk will pay ZymoGenetics a $4 million initial license fee, along with milestone and royalty payments. Novo Nordisk will be responsible for all development activities. Further financial details were not disclosed.
In September 2010, Bristol-Myers Squibb and ZymoGenetics signed definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash. The transaction, with an aggregate purchase price of approximately $885 million, or approximately $735 million net of cash acquired, has been unanimously approved by the boards of directors of both companies. The...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
Additional information available to subscribers only: